The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TRIKAFTA Vertex Pharmaceuticals Australia Pty Ltd
Product name
TRIKAFTA
Accepted date
Apr-2024
Active ingredients
elexacaftor, ivacaftor, tezacaftor
Proposed indication
Trikafta is indicated for the treatment of cystic fibrosis in patients with responsive gene mutations.
Application type
C (new indication)
Publication date
Apr-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.